Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
Arrowhead PharmaceuticalsArrowhead Pharmaceuticals(US:ARWR) Businesswire·2026-07-22 19:30

公司临床研究进展 - Arrowhead Pharmaceuticals公司宣布了其药物plozasiran用于治疗严重高甘油三酯血症的全球3期SHASTA-3和SHASTA-4临床研究的顶线结果 [1] - SHASTA-3和SHASTA-4研究成功达到了与安慰剂相比降低甘油三酯的主要终点 [1] 药物适应症与市场 - 药物plozasiran针对的适应症为严重高甘油三酯血症，该病症会显著增加急性胰腺炎的风险 [1] - 急性胰腺炎与反复住院相关，且可能致命，表明该适应症存在未满足的临床需求 [1]

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia - Reportify